Ingredient guide · Ingredient reference

Amygdalin and “B17”: unsupported cancer claims and cyanide risk

Amygdalin is marketed using names such as laetrile and “B17.” Clinical evidence does not establish a cancer benefit, and cyanide poisoning is a serious risk.

Read the evidence ↓

Supplement Science Insights Editorial Team

Published September 23, 2026

The vitamin label is misleading

MSK describes amygdalin as a plant compound found in sources including apricot kernels. Calling it vitamin B17 does not establish that it is an essential vitamin or that a deficiency causes cancer. Those claims are unsupported. [1]

Clinical findings outweigh a compelling theory

Amygdalin can release cyanide during metabolism. MSK reports that a National Cancer Institute-supported clinical study found no benefit and some participants developed cyanide toxicity. Laboratory anticancer mechanisms do not reverse that clinical finding or demonstrate a safe treatment. [1]

Evaluating a selective-killing claim

Imagine a seller claims a compound harms only abnormal cells. The claim needs evidence in people showing both useful outcomes and acceptable harm to normal tissues. A diagram of a proposed mechanism cannot supply either result. Nor can testimonials identify what would have happened without the product or with appropriate care.

Hypothetical evidence check — not a product recommendation
What a reader seesWhat it actually supports
“B17” used as a marketing nameNot proof of an essential nutrient
Laboratory mechanismCannot replace clinical benefit and safety evidence

Poisoning is not a detox reaction

MSK documents cyanide poisoning following amygdalin or apricot-kernel use, including severe and fatal outcomes. Reported symptoms include vomiting, dizziness, confusion and impaired oxygen delivery. Do not interpret illness after taking such a product as evidence that it is working, and do not use it to replace cancer care. [1]

No purchasing recommendation

This is a safety and evidence page, not a shopping guide. A familiar food source does not establish the safety of a concentrated constituent. The relevant decision is whether credible benefit and acceptable risk have been demonstrated together. The evidence summarized here does not justify selecting a retail product or a self-treatment regimen.

Amygdalin and “B17”: unsupported cancer claims and cyanide risk — original article outline diagram
Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

  1. Memorial Sloan Kettering Cancer Center — Amygdalin and “B17”
    Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.